EUVIMEDEUVIMED entdecken
Crossref

CLO26-111: Treatment-Naïve CLL in Routine Care: Acalabrutinib Monotherapy Versus Acalabrutinib Plus Obinutuzumab

Truman Koh, Ken Zou, Farrukh Awan

Journal of the National Comprehensive Cancer Network · 31.03.2026 · 24 (3.5)

DOI: 10.6004/jnccn.2025.7438 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the National Comprehensive Cancer Network, erschienen am 31.03.2026. Verfasst von Truman Koh und 2 weiteren Autor:innen. Beteiligte Einrichtung: 1University of Texas Southwestern Medical Center, Dallas, TX.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • 1University of Texas Southwestern Medical Center, Dallas, TX.

Zitieren

APA

Koh, T., Zou, K., & Awan, F. (2026). CLO26-111: Treatment-Naïve CLL in Routine Care: Acalabrutinib Monotherapy Versus Acalabrutinib Plus Obinutuzumab. Journal of the National Comprehensive Cancer Network, 24(3.5). https://doi.org/10.6004/jnccn.2025.7438

Vancouver

Koh T, Zou K, Awan F. CLO26-111: Treatment-Naïve CLL in Routine Care: Acalabrutinib Monotherapy Versus Acalabrutinib Plus Obinutuzumab. Journal of the National Comprehensive Cancer Network. 2026;24(3.5). doi:10.6004/jnccn.2025.7438

BibTeX
@article{Koh2026,
  author = {Koh, Truman and Zou, Ken and Awan, Farrukh},
  title = {CLO26-111: Treatment-Naïve CLL in Routine Care: Acalabrutinib Monotherapy Versus Acalabrutinib Plus Obinutuzumab},
  journal = {Journal of the National Comprehensive Cancer Network},
  year = {2026},
  volume = {24},
  number = {3.5},
  doi = {10.6004/jnccn.2025.7438}
}
Kostenlos starten →